Six innovations that support people with respiratory diseases will receive a share of £2.7 million, and eight innovations that help detect, prevent and manage cardiovascular disease are to share £3.3 million in funding.
The programme, led by SBRI Healthcare, an Accelerated Access Collaborative initiative in partnership with the Academic Health Science Networks, aims to support promising new technologies and innovations to gain evidence and real-world validation.
Innovations include digital inhalers for children allowing families to monitor usage via a smartphone; a hybrid digital and in-person programme for pulmonary rehabilitation; a digital platform that allows anyone with a smartphone or tablet to test themselves for a range of major diseases and conditions via fingerprick; an AI-powered patient management system; and a non-invasive screening test for coronary and structural heart diseases.
The awarded respiratory disease innovations:
my mhealth Limited – awarded £499,780
myCOPD enables patients to manage their own COPD by linking with clinical teams, reporting symptoms and key assessments and accessing content to improve their physical wellbeing and quality of life. The project explores its implementation and success in two UK regions.
Lenus Health Ltd – awarded £467,260
Implementing and evaluating the Lenus COPD Support Service for remotely managing chronic obstructive pulmonary disease at Hull University Teaching Hospitals NHS Trust.
Adherium Europe Ltd – awarded £499,871
Smart Digital inhaler enabled asthma management in high-risk children aged five to 16 years, managed in primary care to prevent asthma attacks.
Tiny Medical Apps – awarded £488,525
The Digital Health Passport is an asthma self-management app co-designed with young people and NHS specialists to improve asthma control. MYPASS will measure the impact of the platform on asthma attacks, unscheduled care and steroid use and evaluate three user engagement strategies (nurse-led, social media and NHS comms).
patientMpower – awarded £279,732
A randomised, prospective evaluation of health outcomes, service and health economic impact of hybrid (remote plus clinic) versus clinic alone to enable right-time, right-place care for the follow-up of patients after lung transplantation.
Aseptika Ltd – awarded £499,342
Real-world validation in both community and hospital-based settings for a technology-enabled hybrid service delivery model for pulmonary rehabilitation.
The awarded cardiovascular disease innovations:
Abtrace – awarded £488,640
Clinical intelligent automation software providing end-to-end coverage across multiple pathways and rulesets including cardiovascular disease management and prevention.
PocDoc – awarded £489,521
PocDoc has developed a smartphone-based lipid test which can deliver a five marker lipid panel via the PocDoc app within six minutes, with results shared immediately back with the healthcare system.
Healum Ltd – awarded £390,795
Scale and evaluate the ROI of using the Healum integrated care planning software, patient facing self-management app and live learning research network, in supporting ICS commissioners and multidisciplinary teams in primary care, in order to implement intelligent personalised care and support strategies to patients at risk of cardiovascular disease.
Discover Momenta Ltd – awarded £491,213
Momenta’s cardiovascular disease prevention programme has been co-developed with the South Eastern Trust in Northern Ireland with input from the British Heart Foundation. The project is to optimise scalability across three care pathways in Birmingham and Solihull, enabling rapid subsequent national dissemination.
Huma – awarded £493,877
A digital first, population-level, early detection, engagement and self-management programme for people who are undiagnosed and/or high-risk of developing modifiable cardiovascular disease.
Cardisio GmbH – awarded £342,484
Assessing the impact of using community-based heart testing to detect early signs of cardiovascular disease through a novel, quick, low-cost screener which uses sophisticated AI-based analysis. The Cardisio test is a quick first line triage test, measuring a patient’s electrical heart activity in three dimensions, and is taken at rest in a primary care setting. Test results in three disease areas (CAD, arrythmia, Structural heart disease) are made available to the physician in c.4 minutes.
Inavya Ventures Ltd – awarded £180,564
Avatr is an AI platform that lets doctors input care and medication plans and removes complexity making it easy for patients to follow. During the PoP-60 study, the clinical and economic benefits of Avatr will be evaluated for cardiac patients discharged from hospital.
Southwest London Integrated Care System – awarded £439,069
The CVD prevention decathlon will provide structured education for those at risk of cardiovascular disease. Fusing structured learning and physical activity delivered by Xyla, gamification via the bespoke Sweatcoin app and personalised behaviour change videos via Citizen communications, the aim is to prevent the onset of CVD for local populations.
